What's Happening?
Summit Therapeutics' ivonescimab, an Akeso-partnered PD-1xVEGF bispecific antibody, is drawing significant interest from major biopharmaceutical companies for clinical trial collaborations. These companies are seeking to combine their drugs with ivonescimab, which
has shown potential as an immunotherapy backbone across various tumor types. This surge in interest follows ivonescimab's performance in a China-based head-to-head Phase 3 study in non-small cell lung cancer (NSCLC) in September 2024, where it outperformed Merck's Keytruda. Summit is currently awaiting final progression-free survival (PFS) data from the Phase 3 multiregional HARMONi-3 study, which compares ivonescimab to Keytruda as a frontline treatment for NSCLC, expected before the end of the year. AstraZeneca, for instance, has not only entered into two clinical trial collaborations with Summit but also made a $2 billion equity investment.
Why It's Important?
The intense interest from leading biopharma companies in combining their assets with ivonescimab underscores its potential to become a transformative therapy in oncology. If the HARMONi-3 study data confirms its superiority or non-inferiority to Keytruda, ivonescimab could emerge as a new standard of care, potentially replacing Keytruda as a major backbone treatment in cancer. This would have significant implications for the competitive landscape of the oncology market, which currently sees Keytruda as the most successful cancer drug with over $31 billion in revenue in 2025. The PD-1xVEGF market is projected to exceed $30 billion by 2032, indicating the substantial commercial opportunity for a highly effective drug in this class. The collaborations also highlight a strategic shift towards combination therapies to enhance efficacy and overcome resistance in cancer treatment.
What's Next?
All eyes are on the upcoming announcement of the Phase 3 HARMONi-3 study data for ivonescimab. The results of this multiregional trial will be crucial in determining the drug's future, particularly its potential to gain regulatory approval and widespread adoption outside of China. Ivonescimab is currently under FDA review as a second-line treatment for advanced non-squamous NSCLC, with a decision anticipated on November 14. If the data are positive, it could solidify ivonescimab's position as a leading oncology drug. Further clinical trial collaborations are also expected, as Summit's chief business and strategy officer, Dave Gancarz, indicated ongoing discussions for new partnerships.
Beyond the Headlines
The 'Keytruda killer' nickname for ivonescimab reflects the high expectations and competitive nature of the oncology drug development space. While initial positive data largely came from China-only trials, the upcoming global HARMONi-3 data will be critical for establishing its relevance and efficacy in diverse patient populations. The substantial investments and partnerships by companies like AstraZeneca, Pfizer, and Revolution Medicines demonstrate a proactive strategy to secure a stake in what could be the next generation of blockbuster cancer treatments. This trend suggests a future where combination therapies, leveraging novel mechanisms like PD-1xVEGF, will play an increasingly central role in improving cancer patient outcomes.
